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ADVANCE Praise
Sometimes an artfully crafted quasi-acronym can help distinguish
one otherwise indistinguishable clinical advance from another
(1–3). The infectiousness of this engaging wOrdPlay is evidenced
by a recent report describing the role of Tirofiban for prevention of
iscHEmIc complicatioNS among high-risk pAtieNts undergoIng
coronary angioplasTY (4)—a distinguished advance indeed!
*George A. Diamond, MD, FACC
*2408 Wild Oak Drive




1. The ADVANCE Investigators. Rationale and design of the
ADVANCE study: a randomized trial of blood pressure lowering and
intensive glucose control in high-risk individuals with type 2 diabetes
mellitus. Action in Diabetes and Vascular Disease: PreterAx and
DiamicroN Modified-Release Controlled Evaluation. J Hypertens
Suppl 2001;19 Suppl 4:S21–8.
2. Serruys PW, Foley DP, Suttorp MJ, et al. A randomized comparison of
the value of additional stenting after optimal balloon angioplasty for
long coronary lesions: final results of the additional value of NIR stents
for treatment of long coronary lesions (ADVANCE) study. J Am Coll
Cardiol 2002;39:393–9.
3. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise
end point and design for the ADVANCE (A Dose evaluation of a
Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
Am Heart J 2003;145:179–86.
4. Valgimigli M, Percoco GF, Barbieri D, et al. The additive value of
tirofiban administered with the high dose bolus in the prevention of
ischemic complications during high-risk coronary angioplasty
(ADVANCE) trial. J Am Coll Cardiol 2004;44:14–9.
REPLY
We thank Dr. Diamond for his interest in our recent paper (1).
It can happen that, when a trial is designed, not enough
attention is paid to the (quasi)-acronym used to identify the study.
Unfortunately, it also happens that the medical world finishes
paying more attention to it than to the trial message itself, and that
is not a distinguished advance indeed! But the lesson is clear: from
now on, we will keep ADVANC(E)ing with new STRAT-
EG(Y)ies (2).
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CORRECTION
Chessa M, Butera G, Carminati M. Letter to the Editor: Risk of Thrombus Formation on Devices Used to Close Transcatheter
Atrial Septal Defect and Patent Foramen Ovale. J Am Coll Cardiol 2004;44:1712.
The correct authors’ names are Massimo Chessa, MD, PhD, Gianfranco Butera, MD, PhD, and Mario Carminati, MD.
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